Effects of Omacor and Aspirin on Platelet Function
Completed · Early Phase 1
Conditions studied: Healthy
In brief
Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method.
Key facts
- Study ID
- NCT00688961
- Run by
- Sanford Research
- People needed
- 10
- Starts
- 2007-06-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2008-06-03
Who can join
Age: 21 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subjects may be male or female and between the ages of 21 and 60,
- Non-smokers,
- Taking no medications, vitamin pills, nutritional supplements or herbal preparations.
You may not qualify if…
- Subjects may not have a history of allergic reactions to aspirin, fish or fish oils.
- Birth control pills are not allowed.
- Subject cannot have an allergy to aspirin or to non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, others), naproxen (Aleve, Naprosyn, Anaprox, others), indomethacin (Indocin), or ketoprofen (Orudis KT, Orudis, Oruvail), nabumetone (Relafen), oxaprozin (Daypro), or tartrazine.
- Drinking more than three alcoholic beverages a day
- Having any of the following conditions:
- an ulcer or bleeding in the stomach,
- liver or kidney disease,
- bleeding or blood clotting disorder (e.g., hemophilia),
- congestive heart failure,
- fluid retention,
- heart disease,
- high blood pressure,
- gout,
- asthma,
- arthritis, or
- nasal polyps.
Where it is running
- Sanford Research/USD — Sioux Falls, South Dakota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.